{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:32:14Z","timestamp":1787236334420,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2001,12,1]],"date-time":"2001-12-01T00:00:00Z","timestamp":1007164800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2001,12]]},"DOI":"10.1007\/s11894-001-0068-6","type":"journal-article","created":{"date-parts":[[2007,5,24]],"date-time":"2007-05-24T22:41:47Z","timestamp":1180046507000},"page":"477-483","source":"Crossref","is-referenced-by-count":32,"title":["Extraintestinal manifestations of inflammatory bowel disease"],"prefix":"10.1007","volume":"3","author":[{"given":"Charles N.","family":"Bernstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"68_CR1","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1572-0241.2001.03756.x","volume":"96","author":"CN Bernstein","year":"2001","unstructured":"Bernstein CN, Blanchard JF, Rawsthorne P, Yu N: The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001, 96:1116\u20131122. This is the first North American population-based study assessing the prevalence of PSC, ankylosing spondylitis, iritis, uveitis, pyoderma gangrenosum, and erythema nodosum in IBD.","journal-title":"Am J Gastroenterol"},{"key":"68_CR2","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/oxfordjournals.aje.a009735","volume":"149","author":"CN Bernstein","year":"1999","unstructured":"Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A: The epidemiology of Crohn\u2019s disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol 1999, 149:916\u2013924.","journal-title":"Am J Epidemiol"},{"key":"68_CR3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1055\/s-2001-11153","volume":"39","author":"A Tromm","year":"2001","unstructured":"Tromm A, May D, Almus E, et al.: Cutaneous manifestations in inflammatory bowel disease. Z Gastroenterol 2001, 39:137\u2013144.","journal-title":"Z Gastroenterol"},{"key":"68_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00054725-200102000-00001","volume":"7","author":"S Friedman","year":"2001","unstructured":"Friedman S, Marion JF, Scherl E, et al.: Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel Dis 2001, 7:1\u20137.","journal-title":"Inflamm Bowel Dis"},{"key":"68_CR5","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archsurg.135.5.564","volume":"135","author":"DG Sheldon","year":"2000","unstructured":"Sheldon DG, Sawchuk LL, Kozarek RA, Thirlby RC: Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management. Arch Surg 2000, 135:564\u2013568.","journal-title":"Arch Surg"},{"key":"68_CR6","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/jama.284.12.1546","volume":"284","author":"AP Hughes","year":"2000","unstructured":"Hughes AP, Jackson JM, Callen JP: Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000, 284:1546\u20131548.","journal-title":"JAMA"},{"key":"68_CR7","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1136\/gut.41.5.688","volume":"41","author":"P Kelly","year":"1997","unstructured":"Kelly P, Patchett S, McCloskey D, et al.: Sclerosing cholangitis, race and sex. Gut 1997, 41:688\u2013689.","journal-title":"Gut"},{"key":"68_CR8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/hep.510280207","volume":"28","author":"B Terjung","year":"1998","unstructured":"Terjung B, Herzog V, Worman HJ, et al.: Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology 1998, 28:332\u2013340.","journal-title":"Hepatology"},{"key":"68_CR9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1053\/gast.2000.9366","volume":"119","author":"B Terjung","year":"2000","unstructured":"Terjung B, Spengler U, Sauerbach T, Worman HJ: \u2018Atypical p-ANCA\u2018 in IBD and hepatobiliary disorders reacts with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000, 119:310\u2013322. This study defines the myeloid nuclear antigen(s) to which pANCA in IBD binds.","journal-title":"Gastroenterology"},{"key":"68_CR10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/hep.510270201","volume":"27","author":"A Bergquist","year":"1998","unstructured":"Bergquist A, Glaumann H, Persson B, Broome U: Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case control study. Hepatology 1998, 27:311\u2013316.","journal-title":"Hepatology"},{"key":"68_CR11","first-page":"194","volume":"9","author":"K Herzog","year":"1996","unstructured":"Herzog K, Goldblum JR: Gall bladder adenocarcinoma, acalculous chronic lymphoplasmacytic cholecystitis, ulcerative colitis. Mod Pathol 1996, 9:194\u2013198.","journal-title":"Mod Pathol"},{"key":"68_CR12","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3109\/00365529709025107","volume":"32","author":"HH Rasmussen","year":"1997","unstructured":"Rasmussen HH, Fallingborg JF, Mortensen PB, et al.: Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn\u2019s disease. Scand J Gastroenterol 1997, 32:604\u2013610.","journal-title":"Scand J Gastroenterol"},{"key":"68_CR13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3109\/00365529709000186","volume":"32","author":"B Heikius","year":"1997","unstructured":"Heikius B, Niemela S, Lehtola J, et al.: Hepatobiliary and coexisting pancreatic duct abnormalities in patients with inflammatory bowel disease. Scand J Gastroenterol 1997, 32:153\u2013161.","journal-title":"Scand J Gastroenterol"},{"key":"68_CR14","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1572-0241.1999.01015.x","volume":"94","author":"B Heikius","year":"1999","unstructured":"Heikius B, Niemela S, Lehtola S, Karttunen TJ: Elevated pancreatic enzymes in inflammatory bowel disease are associated with extensive disease. Am J Gastroenterol 1999, 94:1062\u20131079.","journal-title":"Am J Gastroenterol"},{"key":"68_CR15","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/gut.43.5.639","volume":"43","author":"GV Papatheodoridis","year":"1998","unstructured":"Papatheodoridis GV, Hamilton M, Mistry PK, et al.: Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998, 43:639\u2013644.","journal-title":"Gut"},{"key":"68_CR16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/gut.48.4.473","volume":"48","author":"EJ Schoon","year":"2001","unstructured":"Schoon EJ, Muller MCA, Vermeer C, et al.: Low serum and bone vitamin K status in patients with longstanding Crohn\u2019s disease: another pathogenetic factor of osteoporosis in Crohn\u2019s disease? Gut 2001, 48:473\u2013477.","journal-title":"Gut"},{"key":"68_CR17","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/jn\/125.7.1812","volume":"125","author":"NC Binkley","year":"1995","unstructured":"Binkley NC, Suttie JW: Vitamin K nutrition and osteoporosis. J Nutr 1995, 125:1812\u20131821.","journal-title":"J Nutr"},{"key":"68_CR18","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1001\/archinte.159.15.1750","volume":"159","author":"PJ Carraballo","year":"1999","unstructured":"Carraballo PJ, Heit JA, Atkinson EJ, et al.: Long term use of oral anticoagulants and the risk of fracture. Arch Intern Med 1999; 159:1750\u20131756.","journal-title":"Arch Intern Med"},{"key":"68_CR19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0167-5699(00)01718-7","volume":"21","author":"Y-Y Kong","year":"2000","unstructured":"Kong Y-Y, Boyle WJ, Penninger JM: Osteoprotegrin ligand: a regulator of immune response and bone physiology. Immunol Today 2000, 21:495\u2013502. This is a review of the biology of OPGL, a molecule that may be an important link between osteoclastogenesis (and hence osteoporosis) and T-cell biology (and hence systemic inflammation).","journal-title":"Immunol Today"},{"key":"68_CR20","first-page":"147","volume-title":"Trends in Inflammatory Bowel Disease Therapy, 1999","author":"CN Bernstein","year":"1999","unstructured":"Bernstein CN: Risk factors and prevalence of bone disease in inflammatory bowel disease. In Trends in Inflammatory Bowel Disease Therapy, 1999. Edited by Williams CN, Bursey RF, Gall DG, et al. Dordrecht: Kluwer Academic Publishers; 1999:147\u2013162."},{"issue":"suppl 232","key":"68_CR21","first-page":"43","volume":"35","author":"EJ Schoon","year":"2000","unstructured":"Schoon EJ, van Nunen AB, Wouters RSME, et al.: Osteopenia and osteoporosis in Crohn\u2019s disease: prevalence in a Dutch population-based cohort. Scand J Gastroenterol 2000, 35(suppl 232):43\u201347.","journal-title":"Scand J Gastroenterol"},{"key":"68_CR22","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1053\/gast.2000.19280","volume":"119","author":"EJ Schoon","year":"2000","unstructured":"Schoon EJ, Blok BM, Geerling BJ, et al.: Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology 2000, 119:1203\u20131208.","journal-title":"Gastroenterology"},{"key":"68_CR23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/gut.46.2.176","volume":"46","author":"P Vestergaard","year":"2000","unstructured":"Vestergaard P, Krogh K, Rejnmark L, et al.: Fracture risk is increased in Crohn\u2019s disease, but not in ulcerative colitis. Gut 2000, 46:176\u2013181.","journal-title":"Gut"},{"key":"68_CR24","doi-asserted-by":"crossref","first-page":"795","DOI":"10.7326\/0003-4819-133-10-200011210-00012","volume":"133","author":"CN Bernstein","year":"2000","unstructured":"Bernstein CN, Blanchard JF, Leslie W, et al.: The incidence of fractures among patients with IBD: a population-based study. Ann Intern Med 2000, 133:795\u2013799. This is the first population-based study reporting the incidence of fractures in patients with IBD. The incidence is quantified at approximately one fracture\/100 patient-years. Compared with a matched cohort, there was a 40% increased risk of sustaining a fracture.","journal-title":"Ann Intern Med"},{"key":"68_CR25","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1053\/gast.2000.16518","volume":"119","author":"KV Haderslev","year":"2000","unstructured":"Haderslev KV, Tjellesen L, Sorensen HA, Staun M: Alendronate increases lumbar spine bone mineral density in patients with Crohn\u2019s disease. Gastroenterology 2000, 119:639\u2013646.","journal-title":"Gastroenterology"},{"key":"68_CR26","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1053\/gast.2000.18158","volume":"119","author":"CMS Schulte","year":"2000","unstructured":"Schulte CMS, Dignass AU, Goebell H, et al.: Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology 2000, 119:909\u2013920. This interesting study attempted to correlate cytokine genotyping for proinflammatory cytokines with rate of annual bone loss.","journal-title":"Gastroenterology"},{"key":"68_CR27","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1055\/s-0037-1615600","volume":"85","author":"CN Bernstein","year":"2001","unstructured":"Bernstein CN, Blanchard JF, Houston D, Wajda A: The incidence of venous thromboembolic disease among patients with IBD: a population-based study. Thromb Haemost 2001, 85:430\u2013434. This is the first population-based study reporting the incidence of venous thromboembolism in patients with IBD. The incidence is quantified at approximately one venous thrombosis\/200 patientyears. Compared with a matched cohort, there was a threefold to fourfold increased risk of sustaining DVT\/PE.","journal-title":"Thromb Haemost"},{"key":"68_CR28","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/j.1572-0241.2001.03797.x","volume":"96","author":"C Guedon","year":"2001","unstructured":"Guedon C, Le Cam-Duchez V, Lalaude O, et al.: Prothrombotic inherited abnormalities other than factor V Leiden mutation do not play a role in venous thrombosis. Am J Gastroenterol 2001, 96:1448\u20131454.","journal-title":"Am J Gastroenterol"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-001-0068-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11894-001-0068-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-001-0068-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:03:41Z","timestamp":1559419421000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11894-001-0068-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,12]]}},"alternative-id":["68"],"URL":"https:\/\/doi.org\/10.1007\/s11894-001-0068-6","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,12]]}}}